Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas

Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas

Background Histiocytic sarcomas (HS) frequently metastasise, most commonly to visceral sites, but also to regional lymph nodes. Nodal metastases are associated with a poorer prognosis. This retrospective study aimed to evaluate prognostic factors, including the effect of adjuvant chemotherapy, on su...

Full description

Saved in:
Bibliographic Details
Published in:Australian veterinary journal Vol. 95; no. 1-2; pp. 37 - 40
Main Authors: Moore, AS, Taylor, DP, Reppas, G, Frimberger, AE
Format: Journal Article
Language:English
Published: Melbourne Wiley Publishing Asia Pty Ltd 01-01-2017
Wiley Subscription Services, Inc
Subjects:
Animals
cancer
Chemotherapy
Chemotherapy, Adjuvant - veterinary
Dog Diseases - drug therapy
Dog Diseases - pathology
Dog Diseases - surgery
Dogs
Female
histiocytic sarcoma
Histiocytic Sarcoma - drug therapy
Histiocytic Sarcoma - pathology
Histiocytic Sarcoma - surgery
Histiocytic Sarcoma - veterinary
Lymph Nodes - pathology
Lymphatic Metastasis
Lymphatic system
Male
Medical prognosis
Metastasis
oncology
Prognosis
Retrospective Studies
Survival
Survival Analysis
dogs
histiocytic sarcoma
cancer
chemotherapy
oncology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Histiocytic sarcomas (HS) frequently metastasise, most commonly to visceral sites, but also to regional lymph nodes. Nodal metastases are associated with a poorer prognosis. This retrospective study aimed to evaluate prognostic factors, including the effect of adjuvant chemotherapy, on survival in dogs with nodal, but not systemic, metastases from HS. Methods Retrospective case series of 12 dogs with histologically diagnosed HS metastatic to lymph nodes treated with surgery with and without adjuvant chemotherapy. Results All dogs had histological evidence of metastasis to lymph nodes, with no clinical evidence for metastasis to viscera. Eight dogs that received chemotherapy had a median estimated survival of 219 days (range 77–1638 days); 1‐ and 2‐year estimated survival rates were 37.7%. Median survival time for 4 dogs with nodal metastases that did not receive chemotherapy was 57 days (range 39–136 days) with none alive 1 year after surgery Conclusion Survival for dogs with only regional nodal metastases from HS appeared to be improved by adjuvant chemotherapy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0005-0423
1751-0813
DOI:10.1111/avj.12522